Skip to main content

Advertisement

SpringerLink
Log in

Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Aim

To assess and compare the measurement properties of EQ-5D-5L and SF-6Dv2 among lymphoma patients in China.

Methods

A face-to-face survey of Chinese lymphoma patients was conducted at baseline (all types) and follow-up (diffuse large B-cell). EQ-5D-5L and SF-6Dv2 health utility scores (HUSs) were calculated using the respective Chinese value sets. Ceiling effect was assessed by calculating the percentage of respondents reporting the optimal health state. Convergent validity of EQ-5D-5L and SF-6Dv2 was assessed using the Spearman rank correlation coefficient (r) with QLQ-C30 as a calibration standard. Known-groups validity of the two HUSs was evaluated by comparing their scores of patients with different conditions; and their sensitivity was further assessed in the known-groups using relative efficiency (RE). Test–retest reliability and responsiveness was tested using ICC and standardized response mean (SRM), respectively.

Results

Altogether 200 patients were enrolled at baseline and 78 were followed up. No ceiling effect was found for SF-6Dv2 compared to 24.5% for EQ-5D-5L. Correlation between the two HUSs and with QLQ-C30 score was strong (r > 0.5). Each dimension of EQ-5D-5L and SF-6Dv2 had moderate or greater correlations with similar dimensions of QLQ-C30 (r > 0.35). Both EQ-5D-5L and SF-6Dv2 could only a minority known-groups, and the latter may have better sensitivity. EQ-5D-5L had better test–retest reliability (ICC = 0.939); while both of them were responsive to patients with worsened and improved clinical status.

Conclusions

EQ-5D-5L and SF-6Dv2 were found to have good convergent validity and responsiveness, while EQ-5D-5L had better test–retest reliability and higher ceiling effect. Not enough evidence indicates which of the two measures has better known-group validity and sensitivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Availability of data and materials

The data from this study are available from the corresponding author on request.

References

  1. Mugnaini, E.N., Ghosh, N.: Lymphoma. Prim. Care 43(4), 661–675 (2016). https://doi.org/10.1016/j.pop.2016.07.012

    Article  PubMed  Google Scholar 

  2. Shankland, K.R., Armitage, J.O., Hancock, B.W.: Non-Hodgkin lymphoma. Lancet 380(9844), 848–857 (2012). https://doi.org/10.1016/S0140-6736(12)60605-9

    Article  PubMed  Google Scholar 

  3. Xu, R.H., Wong, E.L., Jin, J., Huang, H., Dong, D.: Health-related quality of life measured using EQ-5D in patients with lymphomas. Support. Care Cancer 29(5), 2549–2560 (2021). https://doi.org/10.1007/s00520-020-05774-6

    Article  PubMed  Google Scholar 

  4. Center for disease control and prevention. Leading Cancer Cases and Deaths. [cited 2023 April 20].Available from https://gis.cdc.gov/Cancer/USCS/DataViz.html.

  5. Cao, W., Chen, H.D., Yu, Y.W., Li, N., Chen, W.Q.: Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin. Med. J. (Engl.) 134(7), 783–791 (2021). https://doi.org/10.1097/CM9.0000000000001474

    Article  PubMed  Google Scholar 

  6. Liu, W., Liu, J., Song, Y., et al.: Burden of lymphoma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016. J. Hematol. Oncol. 12(1), 115 (2019). https://doi.org/10.1186/s13045-019-0785-7

    Article  PubMed  PubMed Central  Google Scholar 

  7. Matasar, M.J., Zelenetz, A.D.: Overview of lymphoma diagnosis and management. Radiol. Clin. North Am. 46(2), 175–vii (2008). https://doi.org/10.1016/j.rcl.2008.03.005

    Article  PubMed  Google Scholar 

  8. Hu, S., Chen, N., Lu, K., Zhen, C., Sui, X., Fang, X., Li, Y., Luo, Y., Zhou, X., Wang, X.: The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients. Leukemia Lymphoma. 62(6), 1335–1343 (2021). https://doi.org/10.1080/10428194.2020.1867726

    Article  CAS  PubMed  Google Scholar 

  9. Immanuel, A., Hunt, J., McCarthy, H., van Teijlingen, E., Sheppard, Z.A.: Quality of life in survivors of adult haematological malignancy. Eur. J. Cancer Care 28(4), e13067 (2019). https://doi.org/10.1111/ecc.13067

    Article  Google Scholar 

  10. Haraldstad, K., Wahl, A., Andenæs, R., et al.: A systematic review of quality of life research in medicine and health sciences. Qual. Life Res. 28(10), 2641–2650 (2019). https://doi.org/10.1007/s11136-019-02214-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Fayers, P.M., Machin, D.: Quality of life: the assessment, analysis and reporting of patient-reported outcomes, 3rd edn. Wiley, Hoboken (2016)

    Google Scholar 

  12. Poór, A.K., Rencz, F., Brodszky, V., Gulácsi, L., Beretzky, Z., Hidvégi, B., Holló, P., Kárpáti, S., Péntek, M.: Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual. Life Res. 26(12), 3409–3419 (2017). https://doi.org/10.1007/s11136-017-1699-x

    Article  PubMed  Google Scholar 

  13. Nahvijou, A., Safari, H., Ameri, H.: Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population. Breast cancer (Tokyo, Jpn). 28(4), 937–943 (2021). https://doi.org/10.1007/s12282-021-01230-3

    Article  Google Scholar 

  14. Ameri, H., Safari, H., Poder, T.: Exploring the consistency of the SF-6Dv2 in a breast cancer population. Expert Rev. Pharmacoecon. Outcomes Res. 21(5), 1017–1024 (2021). https://doi.org/10.1080/14737167.2021.1842734

    Article  PubMed  Google Scholar 

  15. Zhou, H.J., Zhang, A., Wei, J., Wu, J., Luo, N., Wang, P.: Psychometric performance of EQ-5D-5L and SF-6DV2 in measuring health status of populations in Chinese university staff and students. BMC Public Health 23(1), 2314 (2023). https://doi.org/10.1186/s12889-023-17208-z

    Article  PubMed  PubMed Central  Google Scholar 

  16. Glaser, A.W., Fraser, L.K., Corner, J., et al.: Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: a cross-sectional survey. BMJ Open 3(4), e002317 (2013). https://doi.org/10.1136/bmjopen-2012-002317

    Article  PubMed  PubMed Central  Google Scholar 

  17. Jefford, M., Ward, A.C., Lisy, K., et al.: Patient-reported outcomes in cancer survivors: a population-wide cross-sectional study. Support. Care Cancer 25(10), 3171–3179 (2017). https://doi.org/10.1007/s00520-017-3725-5

    Article  PubMed  Google Scholar 

  18. Xu, R.H., Wong, E.L., Su, Y., Zhang, H., Zhang, W., Dong, D.: Quantifying the effect of financial burden on health-related quality of life among patients with Non-Hodgkin’s lymphomas. Cancers 12(11), 3325 (2020). https://doi.org/10.3390/cancers12113325

    Article  PubMed  PubMed Central  Google Scholar 

  19. Herdman, M., Kerr, C., Pavesi, M., et al.: Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. J Patient Rep Outcomes. 4(1), 22 (2020). https://doi.org/10.1186/s41687-020-0185-3

    Article  PubMed  PubMed Central  Google Scholar 

  20. Feng, Y., Parkin, D., Devlin, N.J.: Assessing the performance of the EQ-VAS in the NHS PROMs programme. Qual. Life Res. 23(3), 977–989 (2014). https://doi.org/10.1007/s11136-013-0537-z

    Article  PubMed  Google Scholar 

  21. Pan, C.W., Zhang, R.Y., Luo, N., He, J.Y., Liu, R.J., Ying, X.H., Wang, P.: How the EQ-5D utilities are derived matters in Chinese diabetes patients: a comparison based on different EQ-5D scoring functions for China. Qual. Life Res. 29(11), 3087–3094 (2020). https://doi.org/10.1007/s11136-020-02551-0

    Article  PubMed  Google Scholar 

  22. Luo, N., Liu, G., Li, M., Guan, H., Jin, X., Rand-Hendriksen, K.: Estimating an EQ-5D-5L value set for China. Value Health. 20(4), 662–669 (2017). https://doi.org/10.1016/j.jval.2016.11.016

    Article  PubMed  Google Scholar 

  23. Zhang, A., Mao, Z., Wang, Z., Wu, J., Luo, N., Wang, P.: Comparing measurement properties of EQ-5D and SF-6D in East and South-East Asian populations: a scoping review. Expert Rev. Pharmacoecon. Outcomes Res. 23(5), 449–468 (2023). https://doi.org/10.1080/14737167.2023.2189590

    Article  PubMed  Google Scholar 

  24. Brazier, J., Usherwood, T., Harper, R., Thomas, K.: Deriving a preference-based single index from the UK SF-36 Health Survey. J. Clin. Epidemiol. 51(11), 1115–1128 (1998). https://doi.org/10.1016/s0895-4356(98)00103-6

    Article  CAS  PubMed  Google Scholar 

  25. Wu, J., Xie, S., He, X., et al.: Valuation of SF-6Dv2 health states in china using time trade-off and discrete-choice experiment with a duration dimension. Pharmacoeconomics 39(5), 521–535 (2021). https://doi.org/10.1007/s40273-020-00997-1

    Article  PubMed  PubMed Central  Google Scholar 

  26. Aaronson, N.K., Ahmedzai, S., Bergman, B., et al.: The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85(5), 365–376 (1993). https://doi.org/10.1093/jnci/85.5.365

    Article  CAS  PubMed  Google Scholar 

  27. van Roij, J., Kieffer, J.M., van de Poll-Franse, L., Husson, O., Raijmakers, N.J.H., Gelissen, J.: Assessing measurement invariance in the EORTC QLQ-C30. Qual. Life Res. 31(3), 889–901 (2022). https://doi.org/10.1007/s11136-021-02961-8

    Article  PubMed  Google Scholar 

  28. Pilz, M.J., Gamper, E.M., Efficace, F., et al.: EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1036 individuals. BMC Public Health 22(1), 1040 (2022). https://doi.org/10.1186/s12889-022-13211-y

    Article  PubMed  PubMed Central  Google Scholar 

  29. Carbone, P.P., Kaplan, H.S., Musshoff, K., Smithers, D.W., Tubiana, M.: Report of the committee on Hodgkin’s disease staging classification. Can. Res. 31(11), 1860–1861 (1971)

    CAS  Google Scholar 

  30. Wahl, R.L., Jacene, H., Kasamon, Y., Lodge, M.A.: From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50(Suppl 1), 122S–50S (2009). https://doi.org/10.2967/jnumed.108.057307

    Article  CAS  PubMed  Google Scholar 

  31. Xie, S., Wu, J., Chen, G.: Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population. Eur. J. Health Econ. (2023). https://doi.org/10.1007/s10198-023-01566-x

    Article  PubMed  Google Scholar 

  32. Hunger, M., Sabariego, C., Stollenwerk, B., Cieza, A., Leidl, R.: Validity, reliability and responsiveness of the EQ-5D in German stroke patients undergoing rehabilitation. Qual. Life Res. 21(7), 1205–1216 (2012). https://doi.org/10.1007/s11136-011-0024-3

    Article  PubMed  Google Scholar 

  33. Bland, J.M., Altman, D.G.: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476), 307–310 (1986)

    Article  CAS  PubMed  Google Scholar 

  34. Mukaka, M.M.: Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med. J. 24(3), 69–71 (2012)

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Heslin, M., Chua, K.C., Trevillion, K., Nath, S., Howard, L.M., Byford, S.: Psychometric properties of the five-level EuroQoL-5 dimension and Short Form-6 dimension measures of health-related quality of life in a population of pregnant women with depression. BJPsych Open. 5(6), e88 (2019). https://doi.org/10.1192/bjo.2019.71

    Article  PubMed  PubMed Central  Google Scholar 

  36. Osborne, R.H., Hawthorne, G., Lew, E.A., Gray, L.C.: Quality of life assessment in the community-dwelling elderly: validation of the Assessment of quality of life (AQoL) instrument and comparison with the SF-36. J. Clin. Epidemiol. 56(2), 138–147 (2003). https://doi.org/10.1016/s0895-4356(02)00601-7

    Article  PubMed  Google Scholar 

  37. Long, D., Polinder, S., Bonsel, G.J., Haagsma, J.A.: Test-retest reliability of the EQ-5D-5L and the reworded QOLIBRI-OS in the general population of Italy, the Netherlands, and the United Kingdom. Qual. Life Res. 30(10), 2961–2971 (2021). https://doi.org/10.1007/s11136-021-02893-3

    Article  PubMed  PubMed Central  Google Scholar 

  38. McHugh, M.L.: Interrater reliability: the kappa statistic. Biochem. Med. 22(3), 276–282 (2012)

    Article  MathSciNet  Google Scholar 

  39. Kangwanrattanakul, K., Parmontree, P.: Psychometric properties comparison between EQ-5D-5L and EQ-5D-3L in the general Thai population. Qual. Life Res. 29(12), 3407–3417 (2020). https://doi.org/10.1007/s11136-020-02595-2

    Article  PubMed  Google Scholar 

  40. Obradovic, M., Lal, A., Liedgens, H.: Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus short Form-6 dimension (SF-6D) questionnaire in chronic pain. Health Qual. Life Outcomes 11, 110 (2013). https://doi.org/10.1186/1477-7525-11-110

    Article  PubMed  PubMed Central  Google Scholar 

  41. Nahvijou, A., Safari, H., Yousefi, M., Rajabi, M., Arab-Zozani, M., Ameri, H.: Mapping the cancer-specific FACT-B onto the generic SF-6Dv2. Breast Cancer (Tokyo, Jpn). 28(1), 130–136 (2021). https://doi.org/10.1007/s12282-020-01141-9

    Article  Google Scholar 

  42. Yang, Q., Huang, D., Jiang, L., Tang, Y., Zeng, D.: Obtaining SF-6D utilities from FACT-H&N in thyroid carcinoma patients: development and results from a mapping study. Front. Endocrinol. 14, 1160882 (2023). https://doi.org/10.3389/fendo.2023.1160882

    Article  Google Scholar 

  43. Yousefi, M., Nahvijou, A., Sari, A.A., Ameri, H.: Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in patients with colorectal and breast cancer from a developing country. Value Health Reg Issues. 24, 57–66 (2021). https://doi.org/10.1016/j.vhri.2020.06.006

    Article  PubMed  Google Scholar 

  44. Xu, R.H., Dong, D., Luo, N., et al.: Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia. Eur. J. Health Econ. 22(4), 547–557 (2021). https://doi.org/10.1007/s10198-021-01273-5

    Article  PubMed  Google Scholar 

  45. Ye, Z., Sun, L., Wang, Q.: A head-to-head comparison of EQ-5D-5 L and SF-6D in Chinese patients with low back pain. Health Qual. Life Outcomes 17(1), 57 (2019). https://doi.org/10.1186/s12955-019-1137-6

    Article  PubMed  PubMed Central  Google Scholar 

  46. Wu, J., Han, Y., Zhao, F.L., Zhou, J., Chen, Z., Sun, H.: Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients. Health Qual. Life Outcomes 12, 156 (2014). https://doi.org/10.1186/s12955-014-0156-6

    Article  PubMed  PubMed Central  Google Scholar 

  47. Yang, F., Lau, T., Lee, E., Vathsala, A., Chia, K.S., Luo, N.: Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD). Eur. J. Health Econ. 16(9), 1019–1026 (2015). https://doi.org/10.1007/s10198-014-0664-7

    Article  PubMed  Google Scholar 

  48. Li, S., Wang, M., Liu, L., Chen, G.: Which approach is better in eliciting health state utilities from breast cancer patients? Evidence from mainland China. Eur. J. Cancer Care 28(2), e12965 (2019). https://doi.org/10.1111/ecc.12965

    Article  Google Scholar 

  49. McDool, E., Mukuria, C., Brazier, J.: A comparison of the SF-6Dv2 and SF-6D UK utility values in a mixed patient and healthy population. Pharmacoeconomics 39(8), 929–940 (2021). https://doi.org/10.1007/s40273-021-01033-6

    Article  PubMed  PubMed Central  Google Scholar 

  50. Kangwanrattanakul, K.: A comparison of measurement properties between UK SF-6D and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population. Expert Rev. Pharmacoecon. Outcomes Res. 21(4), 765–774 (2021). https://doi.org/10.1080/14737167.2021.1829479

    Article  PubMed  Google Scholar 

  51. Tinelli, M., Ryan, M., Bond, C., Scott, A.: Valuing benefits to inform a clinical trial in pharmacy: do differences in utility measures at baseline affect the effectiveness of the intervention? Pharmacoeconomics 31(2), 163–171 (2013). https://doi.org/10.1007/s40273-012-0012-7

    Article  PubMed  Google Scholar 

  52. Wong, C.K.H., Lang, B.H.H., Yu, H.M.S., Lam, C.L.K.: EQ-5D-5L and SF-6D utility measures in symptomatic benign thyroid nodules: acceptability and psychometric evaluation. Patient 10(4), 447–454 (2017). https://doi.org/10.1007/s40271-017-0220-5

    Article  PubMed  Google Scholar 

  53. Abdin, E., Chong, S.A., Seow, E., et al.: A comparison of the reliability and validity of SF-6D, EQ-5D and HUI3 utility measures in patients with schizophrenia and patients with depression in Singapore. Psychiatry Res. 274, 400–408 (2019). https://doi.org/10.1016/j.psychres.2019.02.077

    Article  PubMed  Google Scholar 

  54. Stavem, K., Frøland, S.S., Hellum, K.B.: Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Qual. Life Res. 14(4), 971–980 (2005). https://doi.org/10.1007/s11136-004-3211-7

    Article  PubMed  Google Scholar 

  55. Slobogean, G.P., Noonan, V.K., O’Brien, P.J.: The reliability and validity of the Disabilities of Arm, Shoulder, and Hand, EuroQol-5D, Health Utilities Index, and Short Form-6D outcome instruments in patients with proximal humeral fractures. J. Shoulder Elbow Surg. 19(3), 342–348 (2010). https://doi.org/10.1016/j.jse.2009.10.021

    Article  PubMed  Google Scholar 

  56. Whitehurst, D.G., Bryan, S.: Another study showing that two preference-based measures of health-related quality of life (EQ-5D and SF-6D) are not interchangeable. But why should we expect them to be? Value Health 14(4), 531–538 (2011). https://doi.org/10.1016/j.jval.2010.09.002

    Article  PubMed  Google Scholar 

  57. Gaujoux-Viala, C., Rat, A.C., Guillemin, F., et al.: Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort. Ann. Rheum. Dis. 71(9), 1478–1483 (2012). https://doi.org/10.1136/annrheumdis-2011-200891

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to all the patients who participated in this study.

Funding

This study was funded by the National Natural Science Foundation of China (Project No. 72274037) awarded to P Wang.

Author information

Author notes

  1. Aixue Zhang and Jing Li have contributed equally to this work.

Authors and Affiliations

  1. School of Public Health, Fudan University, 130 Dong An Road, Shanghai, 200032, China

    Aixue Zhang, Zitong Wang & Pei Wang

  2. Key Lab of Health Technology Assessment, National Health Commission of the People’s Republic of China (Fudan University), Shanghai, China

    Aixue Zhang & Pei Wang

  3. Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People’s Republic of China

    Jing Li & Peng Liu

  4. Centre for Health Economics Research and Modelling Infectious Diseases (CHER-MID), University of Antwerp, Antwerp, Belgium

    Zhuxin Mao

  5. School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China

    Jing Wu

  6. Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore

    Nan Luo

Authors
  1. Aixue Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhuxin Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zitong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nan Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

A-XZ and JL analysed the data and drafted the manuscript. Z-XM revised the manuscript and wrote several sections. A-XZ collected and entered the data. Z-TW performed secondary data entry. PL and PW supervised and quality controlled the study. All authors revised the manuscript and approved it for publication.

Corresponding authors

Correspondence to Peng Liu or Pei Wang.

Ethics declarations

Conflict of interest

All authors declare that they have no competing interests.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Zhongshan Hospital, Fudan University. Informed consent was obtained from all participants.

Consent for publication

All authors have reviewed the final manuscript and consented to publication.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Appendices

Appendix 1

See Appendix Table 8.

Table 8 EQ-5D-5L and SF-6Dv2 dimensions according to their similarities
Full size table

Appendix 2

See Appendix Table 9.

Table 9 EQ-5D-5L and SF-6Dv2 with QLQ-C30 dimensions according to their similarities
Full size table

Appendix 3

See Appendix Table 10.

Table 10 Correlations of the dimensions of EQ-5D-5L and QLQ-C30
Full size table

Appendix 4

See Appendix Table 11.

Table 11 Correlations of the dimensions of SF-6Dv2 and QLQ-C30
Full size table

Appendix 5

See Appendix Table 12.

Table 12 EQ-VAS score, EQ-5D-5L and SF-6Dv2 HUS from two sets of questionnaires
Full size table

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, A., Li, J., Mao, Z. et al. Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China. Eur J Health Econ (2024). https://doi.org/10.1007/s10198-024-01672-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10198-024-01672-4

Keywords

JEL Classification

Search

Navigation